Latest Publications
Praesent lectus leo, convallis id neque nec, ultrices euismod nibh. Sed ac rhoncus quam. Fusce tristique tellus diam, vel porta eros iaculis vitae.
Inhibition of Neuroblastoma Cell Growth by Difluoromethylornithine (DFMO) and Bortezomib through Suppression of LIN28 and MYCN
Rich M, Zhao P, Nagulapally A, Bond J, Saulnier Sholler G. Inhibition of Neuroblastoma Cell Growth by Difluoromethylornithine (DFMO) and Bortezomib through Suppression of LIN28 and MYCN, Journal of Cancer Therapy, June 2017, 8, 561-578
Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma
Maser T, Rich M, Hayes D, Zhao P, Nagulapally AB, Bond J, Saulnier Sholler G. Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma, Cancer Med. 2017 Apr 21. doi: 10.1002/cam4.1065. [Epub[...]
Autologous antibodies that bind neuroblastoma cells
Sun Y, Sholler GS, Shukla GS, Pero SC, Carman CL, Zhao P, Krag DN Autologous antibodies that bind neuroblastoma cells, J Immunol Methods. 2015 Nov;426:35-41; PMID:26210205
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma
Mitchell D, Bergendahl G, Ferguson W, Roberts W, Higgins T, Ashikaga T, DeSarno M, Kaplan J, Kraveka J, Eslin D, Werff AV, Hanna GK, Sholler G, A Phase 1 Trial of TPI 287 as a Single[...]
Autologous antibodies that bind neuroblastoma cells
Sun Y, Sholler GS, Shukla GS, Pero SC, Carman CL, Zhao P, Krag DN Autologous antibodies that bind neuroblastoma cells, J Immunol Methods. 2015 Jul 23. pii: S0022-1759(15)30025-9. doi: 10.1016/j.jim.2015.07.009. [Epub ahead of print]
A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma
Saulnier Sholler G, Gerner EW, Bergendahl G, MacArthur RB, Vander Werff A, Ashikaga T, Bond JP, Ferguson W, Roberts W, Wada RK, Eslin D, Kraveka JM, Kaplan J, Mitchell D, Parikh NS, Neville K, Sender[...]
In The Press
Praesent lectus leo, convallis id neque nec, ultrices euismod nibh. Sed ac rhoncus quam. Fusce tristique tellus diam, vel porta eros iaculis vitae.
On-Going Research
Praesent lectus leo, convallis id neque nec, ultrices euismod nibh. Sed ac rhoncus quam. Fusce tristique tellus diam, vel porta eros iaculis vitae.